Global Diabetic Macular Edema Market- 2020-2027

Global Diabetic Macular Edema Market- 2020-2027

Global Diabetic Macular Edema Market Is Segmented By Therapy Type (Anti-VEGF, Corticosteroids, Other Off-label Drugs), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020-2027

Market Overview
The Global Diabetic Macular Edema Market is expected to grow at a CAGR of 1.1% during the forecasting period (2020-2027).
Diabetic Macular Edema (DME) is the accumulation of fluid in the macula part of the retina due to leaking blood vessels.
DME is a major complication of diabetes and a leading cause of vision loss in persons with diabetes mellitus.
Global Diabetic Macular Edema market is estimated to grow to USD 4.1 billion by 2027.
Market Dynamics
Increasing the prevalence of diabetes is the prime factor driving the growth of the Diabetic Macular Edema market.
Globally, an estimated 422 million adults are living with diabetes.
Besides, substantial R&D investment by pharmaceutical companies and the launch of several promising emerging therapies will fuel market growth.
However, unfavorable reimbursement policies will restrict the market growth.
Market Segmentation
Global Diabetic Macular Edema market report segments the market by therapy type, product type, distribution channel and by region.
Based on the therapy type, the diabetic macular edema market has been classified into anti-VEGF, corticosteroids, and other off-label drugs.
Although laser photocoagulation therapy is being used as standard DME treatment for 25 years, the approval of anti-VEGF has revolutionized the treatment of DME.
Based on the distribution channel, the market has been segmented into Hospital Pharmacy, Retail Pharmacy, and Others.
Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
North America will dominate the market owing to the high prevalence of diabetes, high awareness among people about DME, availability of treatment options and better reimbursement policies in the region.
In 2017, North America accounted for around 51% revenue share of the global market.
Market Competitive Analysis
The report also profiles the following companies of the Diabetic Macular Edema market – Novartis, Roche, Allergan, Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, and Bausch & Lomb Incorporated.
By Therapy Type
Anti-VEGF
Corticosteroids
Other Off-label Drugs
By Product Type
Intravitreal Injections
Intravitreal Implants
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Others
By Region
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
North America (The USA, Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Rest of the World
Why purchase the report?
Visualize the composition of the Diabetic Macular Edema market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
Identify commercial opportunities in the Diabetic Macular Edema market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the market – level 4/5 segmentation.
A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for key products of all major market players.
Target Audience
Equipment Suppliers/ Buyers
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers

Related Reports:
Macular Edema Market
Diabetic Foot Ulcer Market